| |
Anand 1999 |
Braakman 1998b |
Harding 2001 |
Kuokkanen 1999 |
Statius Muller 2003 |
| A. Was the assigned treatment adequately concealed prior to allocation? |
0 |
1 |
1 |
1 |
1 |
| B. Were the outcomes of participants who withdrew described and included in the analysis (intention‐to‐treat)? |
0 |
1 |
0 |
2 |
1 |
| C. Were the outcome assessors blinded to treatment status? |
0 |
0 |
2 |
0 |
2 |
| D. Were the treatment and control group comparable at entry? |
0 |
1 |
1 |
1 |
1 |
| E. Were the treatment providers blind to assignment status? |
0 |
0 |
0 |
0 |
0 |
| F. Were care programmes, other than the trial options, identical? |
0 |
2 |
0 |
0 |
2 |
| G. Were the inclusion and exclusion criteria clearly defined? |
1 |
1 |
1 |
1 |
2 |
| H. Were the interventions clearly defined? |
0 |
2 |
1 |
2 |
2 |
| I. Were the outcome measures used clearly defined? |
1 |
2 |
1 |
2 |
1 |
| J. Were diagnostic tests used in outcome assessment clinically useful? (by outcome) |
1 |
1 |
1 |
1 |
1 |
| K. Was the surveillance active, and of clinically appropriate duration? |
1 |
2 |
0 |
1 |
1 |
